Anticoagulation Overdose When Receiving Anticoagulant Therapy Vitamin K Antagonists Who Had Use Of The Cruciferous Family Green: A Review Of The World’s Medicine
Main Article Content
Abstract
Objective: Study to find out the influence of risk factors that are green vegetables of the cruciferous family that can cause anticoagulation over-dosage drugs who received anticoagulant therapy with vitamin K antagonists.
Methods: Present case series study and review of the medical literature, Study on 5 case series of heart failure, mechanical mitral valve after mitral heart valve surgery, and atrial fibrillation had coagulation disorders who receiving anticoagulant therapy with vitamin K antagonists and have used greens vegetables of the cruciferous family.
Results: A Study on 5 cases of the main disease as atrial fibrillation (AF), heart failure with dilated heart chambers, and artificial heart valve surgery who were using vitamin K antagonist anticoagulants (VKAs) drugs with green vegetables of the Cruciferous family that can cause anticoagulation overdose and was discovered when they were medical examination at an International General Hospital in Vietnam in 2022. Clinical cases found to have anticoagulation overdose including the subcutaneous hemorrhagic bruise and who had an anticoagulant overdose disorder with an INR of 7.32, 5.11, 7.63, 8.22, and 10.91, respectively. We were acutely managed in timely resuscitation and returned the coagulation index to normal.
Conclusion: It is recommended that patients who are using vitamin K anticoagulant drugs, should balance their diet, and limit green vegetables that contain a lot of vitamin K such as the Cruciferous family to avoid possible blood clotting disorders or the bleeding may to happen.
Article Details
References
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. The New England Journal of Medicine 2009; 361 (12): 1139 – 1151.
Palareti G, Leali N, Cocheri S, et al (1996). Bleeding complications of oral anticoagulation treatment: an inception-cohort, prospective collaborative study (ISCOAT). The Lancet 1996; 348 (9025): 423-428.
Watson HG, Baglin T, Laidlaw SL, et al. A comparison of the effectiveness and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin. British Journal of Hematology 2001; 115 (1): 145-149.
Gunther KE, Conway G, Leibach L, et al. Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR > 10. Thrombosis Research 2004; 113 (3-4): 205-209.
Vos M, Esposito G, Edirisinghe JN, et al. Vitamin K2 Is a Mitochondrial Electron Carrier That Rescues Pink1 Deficiency. Science 2012; 336 (6086) 1306 – 10.
Eichinger S. Reversing vitamin K antagonists: making the old new again. American Society of Hematology; 2016 (1): 605 – 611.
Shah M, Tsadok MA, Jackevicius CA, et al. Warfarin Use and the Risk for Stroke and Bleeding in Patients with Atrial Fibrillation Undergoing Dialysis. Circulation 2014; 129 (11): 1196-1203.
Steffel J, Collins R, Antz M, et al. The 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace 2021; 23 (10): 1612 – 1676.
Mladĕnka P, Macáková K, Krčmová LK, et al. Vitamin K – sources, physiological role, kinetics, deficiency, detection, therapeutic use, and toxicity. Nutrition Reviews. 2022; 80 (4): 677-698.